Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Eli Lilly (LLY) PT Lowered to $124 at BMO Capital
November 7, 2018 12:40 PM ESTBMO Capital analyst Alex Arfaei lowered the price target on Eli Lilly (NYSE: LLY) to $124.00 (from $130.00) while maintaining an Outperform rating.
The analyst comments, "Lilly had a mixed, incrementally negative 3Q18, but our thesis is unchanged. Although price pressure in the... More
Eli Lilly & Co. (LLY) Tops Q3 EPS by 4c, Raises FY EPS Guidance
November 6, 2018 6:26 AM EST(Updated - November 6, 2018 6:28 AM EST)
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.39, $0.04 better than the analyst estimate of $1.35. Revenue for the quarter came in at $6.06 billion versus the consensus estimate of $6.05 billion.
GUIDANCE:
Eli Lilly & Co.... More
